Search Results - zhenli+he

82 Results Sort By:
Chemically Modified AMPA Receptor RNA Aptamers Designed for In Vivo Use
" RNA aptamers as glutamate agonists offer potential therapeutics for a range of neurological disorders RSS.HDBackground> Background: < Neurological disorders are increasingly recognized as major causes of death and disability worldwide. Nearly 500,000 cases of brain tumor, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) are...
Published: 5/13/2025   |   Inventor(s): Li Niu, Zhen Huang
Keywords(s): Technologies
Category(s): Technology Classifications > Screens and Assays, Technology Classifications > Research Tools and Reagents, Campus, Campus > University at Albany
Chemically Modified AMPA Receptor RNA Aptamers Designed for In Vivo Use
" RNA aptamers as glutamate agonists offer potential therapeutics for a range of neurological disorders RSS.HDBackground> Background: < Neurological disorders are increasingly recognized as major causes of death and disability worldwide. Nearly 500,000 cases of brain tumor, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) are...
Published: 5/13/2025   |   Inventor(s): Li Niu, Zhen Huang
Keywords(s): Technologies
Category(s): Technology Classifications > Screens and Assays, Technology Classifications > Research Tools and Reagents, Campus, Campus > University at Albany
Potent and Selective Inhibition of a Single AMPA Receptor Subunit by an RNA Aptamer
Inhibitors of AMPA type glutamate ion channels for the treatment of neurological disorders such as ALS, Alzheimer's, and Parkinson's. Background: Ionotropic glutamate receptors (iGluRs) play special roles in brain activities, such as memory and learning, and have been implicated in a variety of neurological diseases, such as post-stroke cellular...
Published: 5/13/2025   |   Inventor(s): Li Niu, Zhen Huang, Yan Han, Congzhou Wang, Jae Seon Park
Keywords(s): RNA, Technologies
Category(s): Technology Classifications > Biomedical Science and Engineering, Campus, Campus > University at Albany
Potent and Selective Inhibition of a Single AMPA Receptor Subunit by an RNA Aptamer
Inhibitors of AMPA type glutamate ion channels for the treatment of neurological disorders such as ALS, Alzheimer's, and Parkinson's. Background: Ionotropic glutamate receptors (iGluRs) play special roles in brain activities, such as memory and learning, and have been implicated in a variety of neurological diseases, such as post-stroke cellular...
Published: 5/13/2025   |   Inventor(s): Li Niu, Zhen Huang, Yan Han, Congzhou Wang, Jae Seon Park
Keywords(s): RNA, Technologies
Category(s): Technology Classifications > Biomedical Science and Engineering, Campus, Campus > University at Albany
Drug Candidate for ALS
RNA aptamers that focus on glutamate receptors are a potential drug candidate for amyotrophic lateral sclerosis (ALS). Background: Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, is a progressive neuromuscular disease for which there is no cure. The disease attacks motor neurons that run from the brain to the spinal cord...
Published: 5/13/2025   |   Inventor(s): Li Niu, Zhen Huang
Keywords(s): ALS, amyotrophic lateral sclerosis, aptamers, drug design, Lou Gehrig's disease, MND, motor neurone disease, RNA
Category(s): Technology Classifications > Biomedical Science and Engineering, Campus > University at Albany
Drug Candidate for ALS
RNA aptamers that focus on glutamate receptors are a potential drug candidate for amyotrophic lateral sclerosis (ALS). Background: Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, is a progressive neuromuscular disease for which there is no cure. The disease attacks motor neurons that run from the brain to the spinal cord...
Published: 5/13/2025   |   Inventor(s): Li Niu, Zhen Huang
Keywords(s): ALS, amyotrophic lateral sclerosis, aptamers, drug design, Lou Gehrig's disease, MND, motor neurone disease, RNA
Category(s): Technology Classifications > Biomedical Science and Engineering, Campus > University at Albany
Solvent-resistant Self-crosslinked Poly(ether imide)s
THE CHALLENGE One of the major challenges facing the commercialization of high-performance polymers like poly(ether imide) lies in balancing their excellent thermal and mechanical properties with the need for strong resistance to harsh organic solvents—an essential requirement in industries such as coatings, electronics, and membranes. While...
Published: 4/16/2025   |   Inventor(s): Guoliang Liu, Zhen Xu, Alan Esker, Gehui Liu
Keywords(s):  
Category(s): Technology Classifications > Chemicals/Materials
Method for Vascular Regeneration and Wound Treatment
Asset/Technology Type Therapeutic Strategy Description of Invention The invention is a therapeutic approach for modulating cellular trans-differentiation and potentially angiogenesis by modulating O-glcnacylation (GlcNAc) of proteins, to treat various conditions. The inventors used existing small molecules to prove the concept in vitro and in vivo....
Published: 5/21/2025   |   Inventor(s): John Cooke, Li Lai
Keywords(s):  
Category(s): Clinical Area, Clinical Area > Cardiovascular, Research Area > Heart and Vascular, Research Area > Regenerative Medicine, Technology Classifications, Technology Classifications > Other
Sensitive Point-of-Care miRNA Detection Using a One-Pot, Isothermal Assay
Rapid, RNA Extraction-Free Detection of miRNAs Biomarkers for Accurate Cancer Diagnosis and Prognosis This CRISPR-Cas12a-based assay allows for the rapid, sensitive detection of microRNAs using a one-pot, isothermal process. MicroRNAs(miRNAs) are endogenous and short, non-coding single-stranded RNAs. They participate in various biological functions...
Published: 5/30/2025   |   Inventor(s): Yong Zeng, He Yan
Keywords(s):  
Category(s): Technology Classifications > Human Health Care > Diagnostics, Technology Classifications > Veterinary > Diagnostics
Method of Treating Obesity-Induced Glucose Intolerance and Liver Fibrosis (UCLA Case No. 2021-323)
UCLA researchers in the School of Engineering have discovered a novel method to treat obesity-induced glucose intolerance and liver fibrosis. BACKGROUND: The CDC reports that 41.9% of adults ages 20 and over are obese. An increased incidence of obesity also increases the rates of comorbidities such at type 2 diabetes mellitus (T2DM), non-alcoholic...
Published: 3/5/2025   |   Inventor(s): Zhen Gu
Keywords(s): glucose intolerance, liver fibrosis, Nanoparticles, Notch signaling pathway, obesity
Category(s): Therapeutics > Metabolism And Endocrinology
1 2 3 4 5 6 7 8 9